Abstract

Approximately 14.4 million Americans are experiencing alcohol use disorder (AUD) and about two-thirds of people who experience drug addiction will relapse, highlighting the need to develop novel and effective treatments. Glucagon-like peptide-1 (GLP-1) is a peptide hormone implicated in the mesocorticolimbic reward system and has become a peptide of interest with respect to its putative inhibitory effects on drug reward. In order to further develop treatments for those diagnosed with AUD, the interplay between GLP-1 receptor signaling and ethanol consumption must be elucidated. In the present study, we investigated the ability of the GLP-1 analogue, exendin-4 (Ex-4), to alter alcohol intake and operant responding for sucrose pellets in order to further understand the role of this compound in mediating reward. We selected multiple sites throughout the prosencephalic and mesencephalic regions of the brain, where we directly administered various doses of Ex-4 to male Sprague Dawley rats. In alcohol investigations, we utilized a two-bottle choice intermittent access protocol. In separate groups of rats, we adopted an operant paradigm in order to examine the effect of Ex-4 on motivated responding for palatable food. Results indicated that GLP-1 receptor signaling effectively suppressed voluntary alcohol intake when injected into the ventral tegmental area (VTA), the accumbens core (NAcC) and shell (NAcS), the dorsomedial hippocampus (DMHipp), and the lateral hypothalamus (LH), which are all structures linked to brain reward mechanisms. The arcuate nucleus (ARcN) and the paraventricular nucleus (PVN) of the hypothalamus were unresponsive, as was the basolateral amygdala (BLA). However, Ex-4 treatment into the ArcN and PVN suppressed operant responding for sucrose pellets. In fact, the VTA, NAcC, NAcS, LH, and the DMHipp all showed comparable suppression of sucrose responding. Overall, our findings suggest that these central structures are implicated in brain reward circuitry, including alcohol and appetitive motivation, which may be mediated by GLP-1 receptor mechanisms. GLP-1, therefore, may play a critical role in modifying addictive behaviors via activation of multiple GLP-1 systems throughout the brain.

Highlights

  • Alcohol is the most widely used and abused intoxicant in the United States, with 139.8 million Americans aged 12 and older having consumed alcohol in the past month and an estimated 14.4 million Americans in the United States aged 12 and older (5.4% of the U.S population) experiencing alcohol use disorder (AUD) in 2018 [1]

  • Previous research has revealed that glucagon-like peptide-1 (GLP-1) plays a critical role in learning, metabolism, motivation, and reward; our goal was to map where these interactions take place in the central nervous system (CNS)

  • Our data support previous findings that GLP-1 analogues reliably decrease both perceived reward and motivation to receive rewards when centrally administered to the nucleus accumbens (NAc) and ventral tegmental area (VTA) [30,34,45,46,47]

Read more

Summary

Introduction

Alcohol is the most widely used and abused intoxicant in the United States, with 139.8 million Americans aged 12 and older having consumed alcohol in the past month and an estimated 14.4 million Americans in the United States aged 12 and older (5.4% of the U.S population) experiencing alcohol use disorder (AUD) in 2018 [1]. AUD is characterized by an impaired ability to limit or control alcohol use despite adverse health, occupational, and social consequences [2]. Psychological, and social interventions for AUD, more than 60% of individuals diagnosed with AUD revert back to hazardous alcohol use post-treatment [3]. GLP-1 is a 30-amino acid peptide hormone derived from preproglucagon and produced in the L-type enteroendocrine cells in response to food intake [8]. GLP-1 serves numerous metabolic functions, including mediating glucose-dependent stimulation of insulin secretion, decreasing gastric emptying, and inhibiting food intake, making GLP-1 agonists novel treatments for Type-2 and Type-3 diabetes [10,11,12]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call